Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.


TSX:GUD - Post by User

Post by gudisgoodon May 17, 2022 4:53am
183 Views
Post# 34688328

Fund Investments

Fund InvestmentsSGS caused $7.2M of unrealized losses; REPL $6.682M of unrealized losses. However, both have been gainers for GUD throughout the whole investment period: $6.5M of gains for SGS and $8.6M of gains for REPL.
 
Regarding potential unrealized losses for Q2, these two could signficantly affect GUD's net income once more:
 

For example, through its strategic fund investment, Knight has recorded life to date unrealized gains on investment in SGS and REPL, refer to Section 10 for further information. However, as at May 10, 2022, SGS’s share price closed at USD 3.38 and USD 14.48 respectively. Should the share price of SGS and REPL remain at this level the Company would record an unrealized loss of approximately $4,151 [USD 3,189] and $1,697 [USD 1,304] respectively. The Company’s Board of Directors regularly reviews and approves equity investment decisions.

<< Previous
Bullboard Posts
Next >>